Overview

ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)

Status:
Terminated
Trial end date:
2019-09-11
Target enrollment:
Participant gender:
Summary
This is an open label study of ATI-502 Topical Solution for the treatment of AA, AU, and AT with the following goals: - To assess the safety, tolerability, and efficacy of ATI-502 Topical Solution in subjects with AA, AU or AT following 24 weeks of treatment with ATI-501 Oral Suspension or Placebo Suspension. - To assess the ability of ATI-502 Topical Solution to maintain or improve hair regrowth in subjects previously treated with ATI-501 Oral Suspension or Placebo Suspension.
Phase:
Phase 2
Details
Lead Sponsor:
Aclaris Therapeutics, Inc.
Treatments:
Pharmaceutical Solutions